Compare Freeport-McMoRan Inc (FCX) vs DENTSPLY SIRONA Inc (XRAY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Freeport-McMoRan Inc vs DENTSPLY SIRONA Inc — how do they compare? Freeport-McMoRan Inc trades at $57.85 (market cap $87.65B), while DENTSPLY SIRONA Inc trades at $13.84 (market cap $2.68B). The key difference: Freeport-McMoRan Inc is far larger — about 32.7× DENTSPLY SIRONA Inc's market cap, and DENTSPLY SIRONA Inc pays the higher dividend (5.04%). Which is the better fit depends on your goals.
| FCX | XRAY | |
|---|---|---|
Market Cap | $87.65B | $2.68B |
Sector | Basic Materials | Health |
52-Week High | $71.73 | $16.85 |
52-Week Low | $35.34 | $9.64 |
Enterprise Value | $94.31B | $4.83B |
Dividend Yield | 0.98% | 5.04% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FCX trades at $58.30, down 5.92% over 24 hours, with a neutral technical signal and bearish moving averages. The stock has consistently beaten earnings estimates, with Q2 2026 expected EPS of $0.60. Revenue grew to $25.92B in 2025, with net income of $2.20B and a net margin of 10.34%. The company maintains strong cash flow from operations of $5.61B and a dividend of $0.15 per share payable in August 2026.
FCX presents a favorable outlook with robust earnings performance and analyst consensus pointing to a $72.94 price target, implying significant upside. However, risks include commodity price volatility, high capital expenditures, and debt levels. The stock's current valuation at a P/E of 32.26 may limit near-term gains if growth moderates.
XRAY trades at $13.76, up 8.35% in 24 hours, with technical indicators showing a bullish trend. The stock has missed earnings estimates for three consecutive quarters, with Q2 2026 EPS expected at $0.36. Revenue declined to $3.68 billion in 2025, and the company reported a net loss of $598 million. Recent news highlights include distribution expansions and new AI-enabled product launches, while analyst sentiment remains mixed with a consensus price target of $13.33.
The outlook for XRAY is cautious due to persistent earnings misses and negative profitability, though technical momentum and strategic initiatives offer some upside potential. Key risks include margin pressure, high debt levels, and soft European demand. Investors should weigh the bullish technical signals against fundamental weaknesses before considering a position.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Freeport-McMoRan Inc
Freeport-McMoRan Inc is an international mining company. It operates geographically diverse assets with proven and probable mineral reserves of copper, gold and molybdenum. The company's portfolio of assets includes the Grasberg minerals district in Indonesia
Read more on FCX →About DENTSPLY SIRONA Inc
Dentsply Sirona Inc is a global manufacturer and distributor of dental supplies and equipment. The company's operating segments include Technologies & Equipment, which is responsible for the design, manufacture, sales, and distribution of products including dental implants, CAD/CAM systems, orthodontic clear aligner products, imaging systems, treatment centers, instruments, as well as certain healthcare device products, primarily catheters
Read more on XRAY →
